We are live on ! Find out more
NVS icon

Novartis

831 hedge funds and large institutions have $20.2B invested in Novartis in 2014 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 307 increasing their positions, 320 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 41

15% more funds holding in top 10

Funds holding in top 10: 5260 (+8)

2% more funds holding

Funds holding: 816831 (+15)

0.68% less ownership

Funds ownership: 10.5%9.82% (-0.68%)

1% less capital invested

Capital invested by funds: $20.5B → $20.2B (-$262M)

4% less repeat investments, than reductions

Existing positions increased: 307 | Existing positions reduced: 320

5% less call options, than puts

Call options by funds: $183M | Put options by funds: $192M

Holders
831
Holders Change
+15
Holders Change %
+1.84%
% of All Funds
23.91%
Holding in Top 10
60
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+15.38%
% of All Funds
1.73%
New
61
Increased
307
Reduced
320
Closed
41
Calls
$183M
Puts
$192M
Net Calls
-$9.15M
Net Calls Change
-$57.2M

NVS Hedge Fund Activity: Q1 2014 in Review

831 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q1 2014, worth a combined $20.2B — down 1.3% from $20.5B a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new NVS positions and 41 closed out — a net gain of 20 holders — while 307 added to existing stakes and 320 trimmed.

The largest buyer was Loomis, Sayles & Company, adding an estimated $68.5M. The largest seller was Brown Brothers Harriman & Co, cutting an estimated $999M.

  • 831 institutional investors held Novartis (NVS) as of Q1 2014, up from 816 in Q4 2013.
  • Funds reported $20.2B of Novartis stock for Q1 2014, down 1.3% quarter-over-quarter.
  • 61 funds opened new Novartis positions in Q1 2014 and 41 closed out, a net change of +20 holders.
  • The largest Novartis buyer in Q1 2014 was Loomis, Sayles & Company, an estimated $68.5M added.
  • The largest Novartis seller in Q1 2014 was Brown Brothers Harriman & Co, an estimated $999M sold.

Based on aggregated 13F filings for Q1 2014.